Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of biotin/Avi-tagged UbPCNA binding to recombinant human N-terminal His-tagged REV1 deletion mutant BRCT/UBM1/UBM2 domain expressed in Escherichia coli BL21(DE3) measured after 1 hr by AlphaScreen assay
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed Citation
Inhibition of REV1 in human WTK1 cells assessed as suppression of 0 to 128 J/m2 UV light-induced HPRT gene mutation by measuring reduction in number of resistant clones at 150 uM dosed Immediately following UVC treatment and measured after 21 hrs
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of REV1 in human HeLa cells assessed as reduction in 2.5 J/m2 UV light-induced cyclopyrimidine dimer removal at 150 uM by epi-fluorescence microscopic analysis
Inhibition of UbPCNA binding to EGFP-tagged REV1 (unknown origin) expressed in human U2OS cells assessed as reduction in cisplatin-induced recruitment of EGFP-REV1 to PCNA foci on chromatin at 150 uM treated after 3.5 hrs cisplatin exposure and measured 6 hrs after post dose by immunostaining based confocal microscopic analysis
Binding affinity to recombinant human REV1 UBM1/UBM2 domain (137 residues) expressed in Escherichia coli BL21(DE3) assessed as increase in NOE peaks at 200 uM by STD NMR spectral analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on